Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Clin Adv Hematol Oncol. 2020 Apr;18(4):212-217.
Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to elucidate the expanding role of immunotherapy.
非小细胞肺癌（NSCLC）占美国肺癌病例的 85%，70%的 NSCLC 患者在诊断时已处于局部晚期或转移性疾病。局部晚期 NSCLC 患者的 5 年总生存率为 15%至 20%。不可切除的局部晚期 NSCLC 的传统治疗模式包括铂类化疗联合放疗。来自 3 期临床试验的证据确立了放化疗后免疫治疗的作用，新出现的数据继续阐明免疫治疗的扩展作用。
